Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Predictive Value of Serum Glial Fibrillary Acidic Protein and Ubiquitin Carboxy-terminal Hydrolase L1 for Subarachnoid Haemorrhage

NCT06581757 is registered in ClinicalTrials.gov with The Royal Wolverhampton Hospitals NHS Trust as lead sponsor.

NCT NCT06581757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06581757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Predictive Value of Serum Glial Fibrillary Acidic Protein and Ubiquitin Carboxy-terminal Hydrolase L1 for Subarachnoid Haemorrhage
Lead sponsor
The Royal Wolverhampton Hospitals NHS Trust
Phase
Observational
Overall status
Terminated
Start date
January 16, 2025
Completion date
April 28, 2025
Enrollment
144 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

subarachnoid haemorrhage (sah)